Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0013384
Disease: Dyskinetic syndrome
Dyskinetic syndrome
0.080 Biomarker disease BEFREE The beta band power correlated in both experimental sessions with the patient's clinical state (Pearson correlation coefficient <i>r</i> = 0.506, <i>p</i> < 0.001, and <i>r</i> = 0.477, <i>p</i> < 0.001). aDBS after LFP changes was effective (30% improvement without medication [3-way analysis of variance, interaction day × medication <i>p</i> = 0.036; 30.5 ± 3.4 vs 22.2 ± 3.3, <i>p</i> = 0.003]), safe, and well tolerated in patients performing regular daily activities and taking additional dopaminergic medication. aDBS was able to decrease DBS amplitude during motor "on" states compared to "off" states (paired <i>t</i> test <i>p</i> = 0.046), and this automatic adjustment of STN-DBS prevented dyskinesias. 29444973 2018
CUI: C0013384
Disease: Dyskinetic syndrome
Dyskinetic syndrome
0.080 Biomarker disease BEFREE Is bilateral STN DBS more, less, or as effective as bilateral GPi DBS in treating dyskinesias associated with Parkinson's disease? 29538685 2018
CUI: C0013384
Disease: Dyskinetic syndrome
Dyskinetic syndrome
0.080 Biomarker disease BEFREE Bilateral subthalamic nucleus DBS holds the most promising results for patients with tremor, severe motor fluctuations and dyskinesias from L-dopa, with the best improvements seen in daily activities and quality of life. 12869808 2003
CUI: C0013384
Disease: Dyskinetic syndrome
Dyskinetic syndrome
0.080 Biomarker disease BEFREE One patient had bilateral globus pallidal DBS at the age of 33 with marked reduction in dyskinesia, which resulted in mild functional improvement. 27061943 2016
CUI: C0013384
Disease: Dyskinetic syndrome
Dyskinetic syndrome
0.080 GeneticVariation disease BEFREE This systematic review has analyzed the currently available literature reporting cases with either tardive dystonia or dyskinesia treated with DBS. 29433807 2018
CUI: C0013384
Disease: Dyskinetic syndrome
Dyskinetic syndrome
0.080 Biomarker disease BEFREE However, it remains elusive whether stimulation-induced dyskinesias can guide DBS programming. 31571277 2019
CUI: C0013384
Disease: Dyskinetic syndrome
Dyskinetic syndrome
0.080 Biomarker disease BEFREE A multiple regression model (adjusted for disease severity, disease duration, active contacts above the STN, use of amantadine, high pre-operative levodopa-equivalent dose (LED), sex, and interaction between active contacts above the STN and amantadine use) was created to describe the relationship between dyskinesia scores and LED prior to DBS. 31494731 2019
CUI: C0013384
Disease: Dyskinetic syndrome
Dyskinetic syndrome
0.080 Biomarker disease BEFREE In this study, we identified dyskinesias reduction and distance between the active electrodes and the third ventricle as determining factors of weight gain after STN-DBS implantation in PD patients. 28913772 2017